Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorAbajo, A. (Ana)-
dc.creatorRodriguez, J. (Javier)-
dc.creatorBitarte, N. (Nerea)-
dc.creatorZarate, R. (Ruth)-
dc.creatorBoni, V. (Valentina)-
dc.creatorPonz, M. (Mariano)-
dc.creatorChopitea, A. (Ana)-
dc.creatorBandres, E. (Eva)-
dc.creatorGarcia-Foncillas, J. (Jesús)-
dc.date.accessioned2014-08-23T11:03:54Z-
dc.date.available2014-08-23T11:03:54Z-
dc.date.issued2010-
dc.identifier.citationAbajo A, Rodríguez J, Bitarte N, Zarate R, Boni V, Ponz M, et al. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer. 2010 Nov 9;103(10):1529-1535es_ES
dc.identifier.issn0007-0920-
dc.identifier.urihttp://hdl.handle.net/10171/36370-
dc.description.abstractBACKGROUND: To determine the dose-limiting toxicity (DLT), maximum tolerated dose, recommended dose (RD) and preliminary evidence of activity of escalating doses of irinotecan (CPT-11) fixed-dose-rate infusional gemcitabine (FDR-GMB) and bevacizumab in pretreated metastatic colorectal cancer (mCRC) patients. Pharmacogenomic analysis was performed to investigate the association between VEGF single-nucleotide polymorphisms and clinical outcome. PATIENTS AND METHODS: A total of 89 mCRC patients were recruited in a two-step study design; 28 were included in the dose-finding study and 59 in the pharmacogenomic analysis. The FDR-GMB of 1000 mg m⁻², bevacizumab 5 mg kg⁻¹ and CPT-11 doses ranging from 100 to 160 mg m⁻² were explored. The VEGF protein serum levels were quantified by EIA. Allelic discrimination was performed to genotype polymorphisms in the VEGF gene. RESULTS: CPT-11 RD was 150 mg m⁻². Diarrhoea and neutropenia were the DLT. After a median follow-up of 42 months, the median time to progression (TTP) and overall survival were 5.2 and 19.9 months, respectively. VEGF levels were significantly correlated with VEGF-2578AA and VEGF-460CC genotypes, and a trend was observed with VEGF+405GG genotype. The presence of any of these genotypes correlated with a longer median TTP (8.8 vs 4.5 months, P=0.04). CONCLUSION: The triplet combination tested in this study is effective and well tolerated. A possible predictive role for VEGF gene polymorphisms and baseline VEGF circulating levels is suggested.es_ES
dc.language.isoenges_ES
dc.publisherCancer Research UKes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectAntibodies, Monoclonales_ES
dc.subjectBevacizumabes_ES
dc.subjectIrinotecanes_ES
dc.subjectGemcitabinees_ES
dc.subjectColorectal Neoplasms/pathologyes_ES
dc.titleDose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1038/sj.bjc.6605908es_ES

Ficheros en este registro:
Fichero: 
6605908a.pdf
Descripción: 
Tamaño: 
306,78 kB
Formato: 
Adobe PDF


Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.